Green light for Novartis’ lung cancer combination therapy
admin 23rd June 2017 Uncategorised 0Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
More: Green light for Novartis’ lung cancer combination therapy
Source: News